ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Recommendation of “Hold” from Analysts

ACADIA Pharmaceuticals Inc. (NASDAQ:ACADGet Rating) has been assigned an average rating of “Hold” from the twenty research firms that are currently covering the stock, MarketBeat reports. Ten investment analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $29.48.

A number of research analysts recently commented on the company. Canaccord Genuity Group upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price objective for the stock from $30.00 to $31.00 in a research note on Wednesday, March 16th. Zacks Investment Research upgraded ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating and set a $28.00 price objective for the company in a research note on Wednesday, March 23rd. HC Wainwright upgraded ACADIA Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $18.00 to $36.00 in a research note on Wednesday, February 9th. Citigroup upped their price objective on ACADIA Pharmaceuticals from $30.00 to $32.00 in a research note on Tuesday, March 1st. Finally, Canaccord Genuity Group upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price objective for the stock from $30.00 to $31.00 in a research note on Wednesday, March 16th.

Shares of ACAD stock traded up $0.85 on Friday, hitting $17.08. 1,327,803 shares of the stock traded hands, compared to its average volume of 1,539,021. The company has a market capitalization of $2.76 billion, a PE ratio of -12.84 and a beta of 0.67. ACADIA Pharmaceuticals has a 1-year low of $15.16 and a 1-year high of $28.06. The company’s fifty day moving average is $21.07 and its 200 day moving average is $22.35.

ACADIA Pharmaceuticals (NASDAQ:ACADGet Rating) last posted its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.21). The firm had revenue of $115.47 million for the quarter, compared to analyst estimates of $122.22 million. ACADIA Pharmaceuticals had a negative net margin of 43.50% and a negative return on equity of 40.52%. The business’s revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.42) earnings per share. On average, analysts predict that ACADIA Pharmaceuticals will post -1.41 earnings per share for the current fiscal year.

In other ACADIA Pharmaceuticals news, insider James Kihara sold 1,025 shares of the company’s stock in a transaction dated Friday, April 8th. The stock was sold at an average price of $27.05, for a total value of $27,726.25. Following the transaction, the insider now directly owns 2,433 shares of the company’s stock, valued at approximately $65,812.65. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, President Srdjan R. Stankovic sold 2,865 shares of the company’s stock in a transaction dated Monday, May 2nd. The stock was sold at an average price of $18.18, for a total value of $52,085.70. Following the completion of the transaction, the president now directly owns 55,188 shares in the company, valued at $1,003,317.84. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,819 shares of company stock valued at $205,781. Company insiders own 28.50% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. increased its holdings in shares of ACADIA Pharmaceuticals by 8.7% during the 4th quarter. Russell Investments Group Ltd. now owns 138,950 shares of the biopharmaceutical company’s stock valued at $3,241,000 after acquiring an additional 11,172 shares during the last quarter. Rockefeller Capital Management L.P. increased its holdings in shares of ACADIA Pharmaceuticals by 21.4% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 281,228 shares of the biopharmaceutical company’s stock valued at $4,671,000 after acquiring an additional 49,644 shares during the last quarter. Advisor Group Holdings Inc. increased its holdings in shares of ACADIA Pharmaceuticals by 10.0% during the 4th quarter. Advisor Group Holdings Inc. now owns 26,485 shares of the biopharmaceutical company’s stock valued at $623,000 after acquiring an additional 2,399 shares during the last quarter. First Quadrant L P CA increased its holdings in shares of ACADIA Pharmaceuticals by 37.5% during the 4th quarter. First Quadrant L P CA now owns 16,500 shares of the biopharmaceutical company’s stock valued at $385,000 after acquiring an additional 4,500 shares during the last quarter. Finally, Bioimpact Capital LLC acquired a new position in shares of ACADIA Pharmaceuticals during the 4th quarter valued at about $2,918,000. 91.74% of the stock is currently owned by institutional investors.

About ACADIA Pharmaceuticals (Get Rating)

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

See Also

Analyst Recommendations for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.